ID   ClearCa-6
AC   CVCL_X575
SY   clearCa-6
DR   cancercelllines; CVCL_X575
DR   Cosmic; 972662
DR   IARC_TP53; 23211
DR   Wikidata; Q54813626
RX   CelloPub=CLPUB00407;
RX   PubMed=9146668;
RX   PubMed=10925357;
RX   PubMed=11139287;
RX   PubMed=15863265;
CC   Doubling time: 45 hours (PubMed=9146668).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg290His (c.869G>A); ClinVar=VCV000127825; Zygosity=Unspecified (PubMed=11139287; PubMed=15863265).
CC   Sequence variation: Mutation; HGNC; HGNC:12687; VHL; Simple; p.Leu178Glnfs (c.532_533insC); Zygosity=Unspecified (PubMed=10925357).
DI   NCIt; C4033; Clear cell renal cell carcinoma
DI   ORDO; Orphanet_319276; Clear cell renal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   59Y
CA   Cancer cell line
DT   Created: 05-09-14; Last updated: 19-12-24; Version: 11
//
RX   CelloPub=CLPUB00407;
RA   Krieg A.;
RT   "Characterization and functional analysis of the TRAIL system and
RT   the inhibitor of apoptosis protein (IAP) family in human neoplasia.";
RL   Thesis MD (2005); Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany.
//
RX   PubMed=9146668; DOI=10.1016/S0022-5347(01)64778-5;
RA   Ramp U., Jaquet K., Reinecke P., Schardt C., Friebe-Hoffmann U.,
RA   Nitsch T., Marx N., Gabbert H.E., Gerharz C.-D.;
RT   "Functional intactness of stimulatory and inhibitory autocrine loops
RT   in human renal carcinoma cell lines of the clear cell type.";
RL   J. Urol. 157:2345-2350(1997).
//
RX   PubMed=10925357; DOI=10.1002/1097-0215(20000901)87:5<650::AID-IJC5>3.0.CO;2-3;
RA   Meyer A.J., Hernandez A., Florl A.R., Enczmann J., Gerharz C.-D.,
RA   Schulz W.A., Wernet P., Ackermann R.;
RT   "Novel mutations of the von Hippel-Lindau tumor-suppressor gene and
RT   rare DNA hypermethylation in renal-cell carcinoma cell lines of the
RT   clear-cell type.";
RL   Int. J. Cancer 87:650-653(2000).
//
RX   PubMed=11139287; DOI=10.1038/sj.cdd.4400746;
RA   Dejosez M., Ramp U., Mahotka C., Krieg A., Walczak H., Gabbert H.E.,
RA   Gerharz C.-D.;
RT   "Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell
RT   carcinomas and its enhancement by topotecan.";
RL   Cell Death Differ. 7:1127-1136(2000).
//
RX   PubMed=15863265; DOI=10.1016/j.canlet.2004.09.045;
RA   Reinecke P., Kalinski T., Mahotka C., Schmitz M., Dejosez M.,
RA   Gabbert H.E., Gerharz C.-D.;
RT   "Paclitaxel/taxol sensitivity in human renal cell carcinoma is not
RT   determined by the p53 status.";
RL   Cancer Lett. 222:165-171(2005).
//